Menlo Therapeutics Inc

61 articles with Menlo Therapeutics Inc

• Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

  9/8/2020

  VYNE Therapeutics Inc. completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.

• Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics

  9/2/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today it is changing its corporate name to VYNE Therapeutics Inc.  (“VYNE Therapeutics”).

• Menlo Reports Second Quarter 2020 Financial Results and Provides Business UpdateConference Call Today at 8:30am Eastern Time

  8/6/2020

  Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

• Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6

  7/28/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its financial results for the second quarter ended June 30, 2020, on Thursday, August 6, before the market opens. Menlo will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the fin

• 

  Clinical Catch-Up: May 31-June 5

  6/8/2020

  As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

• Menlo Therapeutics Announces Pricing of Offering of Common Stock - June 05, 2020

  6/5/2020

  Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced the pricing of an underwritten public offering of 27,050,000 shares of common stock at a price to the public of $1.85 per share.

• Menlo Therapeutics Announces Proposed Offering of Common Stock

  6/4/2020

  Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering

• Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

  6/2/2020

  The Company plans to present trial data along with a proposed Phase 3 development program in an End of Phase 2 meeting with the FDA before the end of this year

• 

  FDA Action Alert: Foamix, Immunomedics and Merck

  6/1/2020

  Although the U.S. FDA is very busy dealing with emergency use approvals for diagnostics and possible treatments for COVID-19, it is still evaluating and approving therapies for non-COVID-19 indications. Here’s a look at this week’s calendar.

• Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

  5/29/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI

• Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for RosaceaZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults

  5/29/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI™ (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults.

• Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary

  5/27/2020

  Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ ® (min

• Menlo Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/26/2020

  Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020.

• Menlo Reports First Quarter 2020 Financial Results and Provides Business Update

  5/11/2020

  Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

• Menlo Therapeutics to Report First Quarter 2020 Financial Results on May 11

  5/5/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it will report its financial results for the first quarter ended March 31, 2020, on Monday, May 11, before the market opens. Menlo will host a conference call and webcast at 8:30 a.m. Eastern Time on Monday, May 11 to di

• Menlo Therapeutics and Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater ChinaTransaction provides non-dilutive capital including $10M up-front

  4/23/2020

  Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd., has entered into a licensing agreement with specialty pharmaceutical company Cutia Therapeutics Limited, an affiliate of Cutia Therapeutics for AMZEEQ™ topical foam, 4% as well as its other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.

• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  Menlo’s Serlopitant for Prurigo Nodularis Itching Flunks Two Phase III Trials

  4/6/2020

  Menlo Therapeutics released topline results from two Phase III trials of once daily oral serlopitant for pruritus (itching) associated with prurigo nodularis. Neither trial met their primary endpoint.

• Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo NodularisConference call today at 8.30am EDT

  4/6/2020

  Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis (PN), studies MTI-105 and MTI-106

• Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues

  4/2/2020

  Menlo Therapeutics Inc. announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea® Foam.